ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: 6 days ago, 6:31PM

228.72

-4.14 (-1.78%)

  • 1D -1.78%
  • 5D 2.82%
  • 1M 3.60%
  • 6M 10.20%
  • YTD -0.26%
  • 1Y 12.04%
  • 5Y 113.10%
Previous Close 232.86
Open 234.00
Volume 4,364,300
Avg. Volume (3M) 6,562,888
Market Cap 404,236,206,080
Price / Earnings (TTM) 97.33
Price / Earnings (Forward) 15.29
Price / Sales 6.40
Price / Book 50.46
52 Weeks Range
164.39 (-28%) — 244.81 (7%)
Earnings Date 1 May 2026
TTM Dividend Yield 0.72%
Profit Margin 7.31%
Operating Margin (TTM) 30.43%
Diluted EPS (TTM) 2.35
Quarterly Revenue Growth (YOY) 8.40%
Quarterly Earnings Growth (YOY) -6.10%
Total Debt/Equity (MRQ) 4,789.60%
Current Ratio (MRQ) 0.760
Operating Cash Flow (TTM) 16.40 B
Levered Free Cash Flow (TTM) 16.94 B
Return on Assets (TTM) 8.34%
Return on Equity (TTM) 88.40%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock AbbVie Inc. Bearish Bullish

AIStockmoo Score

0.1
Analyst Consensus -0.5
Insider Activity NA
Price Volatility -0.5
Technical Moving Averages -2.5
Technical Oscillators 4.0
Average 0.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABBV 404 B 0.72% 97.33 50.46
JNJ 594 B 0.50% 22.31 7.19
MRK 303 B 0.67% 16.68 4.56
PFE 154 B 1.58% 19.96 1.74
BMY 124 B 4.84% 17.53 5.34
GSK 123 B 1.62% 16.19 5.24

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 74.87%
52 Weeks Range
164.39 (-28%) — 244.81 (7%)
Price Target Range
228.00 (-0%) — 299.00 (30%)
High 299.00 (Piper Sandler, 30.73%) Buy
Median 265.00 (15.86%)
Low 228.00 (Evercore ISI Group, -0.32%) Buy
Average 256.71 (12.24%)
Total 5 Buy, 2 Hold
Avg. Price @ Call 223.37
Firm Date Target Price Call Price @ Call
Barclays 20 Feb 2026 275.00 (20.23%) Buy 228.72
Piper Sandler 18 Feb 2026 299.00 (30.73%) Buy 228.72
Evercore ISI Group 05 Feb 2026 228.00 (-0.31%) Buy 219.02
Morgan Stanley 05 Feb 2026 270.00 (18.05%) Buy 219.02
12 Dec 2025 269.00 (17.61%) Buy 223.32
UBS 05 Feb 2026 230.00 (0.56%) Hold 219.02
07 Jan 2026 240.00 (4.93%) Hold 233.42
Citigroup 27 Jan 2026 230.00 (0.56%) Hold 223.93
HSBC 10 Dec 2025 265.00 (15.86%) Buy 225.18

No data within this time range.

  • 3M
Date Type Details
04 Feb 2026 Announcement AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
03 Feb 2026 Announcement Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
03 Feb 2026 Announcement AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
30 Jan 2026 Announcement $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
29 Jan 2026 Announcement AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
28 Jan 2026 Announcement Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
16 Jan 2026 Announcement AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
12 Jan 2026 Announcement AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
12 Jan 2026 Announcement West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
12 Jan 2026 Announcement AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
12 Jan 2026 Announcement AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
07 Jan 2026 Announcement AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
05 Jan 2026 Announcement AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
14 Dec 2025 TheFinance 3 US Dividend Stocks Every Singapore Investor Should Know
02 Dec 2025 Announcement AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
28 Nov 2025 Announcement SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
25 Nov 2025 Announcement AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
Show more
TTM Dividend Yield 0.72%
5Y Average Dividend Yield 3.22%
Payout Ratio 268.80%
Expected Next Dividend Payment May 2026
Ex Date Announcement Date Payment Date Details
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Cash
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Cash
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Cash
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Cash
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria